In a report released today, Jonathan Hughes from Raymond James maintained a Buy rating on Sabra Healthcare REIT (NASDAQ: SBRA), with a price target of $24. The company’s shares closed yesterday at $22.87, close to its 52-week high of $23.79.
According to TipRanks.com, Hughes is a 3-star analyst with an average return of 4.3% and a 59.6% success rate. Hughes covers the Financial sector, focusing on stocks such as Senior Housing Properties Trust, Physicians Realty Trust, and Omega Healthcare.
Sabra Healthcare REIT has an analyst consensus of Strong Buy, with a price target consensus of $24.25, representing a 6.0% upside. In a report issued on August 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $25 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.79 and a one-year low of $15.78. Currently, Sabra Healthcare REIT has an average volume of 1.36M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sabra Health Care REIT, Inc. engages in managing and investing in healthcare-related real estate properties. It focuses on the acquisition, financing, and owning real estate property to be leased to third party tenants in the healthcare sector. The company was founded on May 10, 2010 and is headquartered in Irvine, CA.
